Jian-Jhong Wang

Dr. Jian-Jhong Wang


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2017 in Scientific Reports
Verified
Journal Article
Open access
VWVin-Cent Wu
Vin-Cent Wu
SWShuo-Meng Wang
Shuo-Meng Wang
SCShih-Chieh Jeff Chueh
Shih-Chieh Jeff Chueh
SYShao-Yu Yang
Shao-Yu Yang
KHKuo-How Huang
Kuo-How Huang
KWKwan-Dun Wu
Kwan-Dun Wu
Constitutive activation of the Wnt pathway/β-catenin signaling may be important in aldosterone-producing adenoma (APA). However, significant gaps remain in our understanding of the prevalence and clinical outcomes after adrenalectomy in APA patients harboringCTNNB1mutations. The molecular expression of CYP11B2 and gonadal receptors in adenomas were also explored. Adenomas from 219 APA patients (95 men; 44.2%; aged 50.5 ± 11.9 years) showed a high rate of somatic mutations (n = 128, 58.4%). The majority of them harboredKCNJ5mutations (n = 116, 52.9%); 8 patients (3.7%, 6 women) hadCTNNB1mutations. Patients with APAs harboringCTNNB1mutations were older and had shorter duration of hypertension. After adrenalectomy,CTNNB1mutation carriers had a higher possibility (87.5%) of residual hypertension than other APA patients. APAs harboringCTNNB1mutations have heterogeneous staining of β-catenin and variable expression of gonadal receptors and both CYP11B1 and CYP11B2. This suggests thatCTNNB1mutations may be more related to tumorigenesis rather than excessive aldosterone production.

26 April 2018 in Critical Care
Verified
Journal Article
Open access
PDF file
JWJian-Jhong Wang
Jian-Jhong Wang
NCNai-Hsin Chi
Nai-Hsin Chi
THTao-Min Huang
Tao-Min Huang
RCRory Connolly
Rory Connolly
LCLiang Wen Chen
Liang Wen Chen
KWKwan-Dun Wu
Kwan-Dun Wu
Acute kidney injury (AKI) after cardiovascular surgery is a serious complication. Little is known about the ability of novel biomarkers in combination with clinical risk scores for prediction of advanced AKI. In this prospectively conducted multicenter study, urine samples were collected from 149 adults at 0, 3, 6, 12 and 24 h after cardiovascular surgery. We measured urinary hemojuvelin (uHJV), kidney injury molecule-1 (uKIM-1), neutrophil gelatinase-associated lipocalin (uNGAL), α-glutathione S-transferase (uα-GST) and π-glutathione S-transferase (uπ-GST). The primary outcome was advanced AKI, under the definition of Kidney Disease: Improving Global Outcomes (KDIGO) stage 2, 3 and composite outcomes were KDIGO stage 2, 3 or 90-day mortality after hospital discharge. Patients with advanced AKI had significantly higher levels of uHJV and uKIM-1 at 3, 6 and 12 h after surgery. When normalized by urinary creatinine level, uKIM-1 in combination with uHJV at 3 h post-surgery had a high predictive ability for advanced AKI and composite outcome (AUC = 0.898 and 0.905, respectively). The combination of this biomarker panel (normalized uKIM-1, uHJV at 3 h post-operation) and Liano’s score was superior in predicting advanced AKI (AUC = 0.931, category-free net reclassification improvement of 1.149, and p < 0.001). When added to Liano’s score, normalized uHJV and uKIM-1 levels at 3 h after cardiovascular surgery enhanced the identification of patients at higher risk of progression to advanced AKI and composite outcomes.

1 January 2017 in Annals of Intensive Care
Verified
Journal Article
Open access
PDF file
TLTai-Shuan Lai
Tai-Shuan Lai
Chih-Chung ShiaoChih-Chung Shiao
Chih-Chung Shiao
JWJian-Jhong Wang
Jian-Jhong Wang
CHChun-Te Huang
Chun-Te Huang
PWPei-Chen Wu
Pei-Chen Wu
VWVin-Cent Wu
Vin-Cent Wu
Although the optimal timing of initiation of renal replacement therapy (RRT) in critically ill patients with acute kidney injury has been extensively studied in the past, it is still unclear. In this systematic review, we searched all related randomized controlled trials (RCTs) that directly compared earlier and later RRT published prior to June 25, 2016, from PubMed, MEDLINE, and EMBASE. We extracted the study characteristics and outcomes of all-cause mortality, RRT dependence, and intensive care unit (ICU) and hospital length of stay (LOS). We identified 51 published relevant studies from 13,468 screened abstracts. Nine RCTs with 1627 participants were included in this meta-analysis. Earlier RRT was not associated with benefits in terms of mortality [relative risk (RR) 0.88, 95% confidence interval (CI) 0.68–1.14, p = 0.33] and RRT dependence (RR 0.81, 95% CI 0.46–1.42, p = 0.46). There were also no significant differences in the ICU and hospital LOS between patients who underwent earlier versus later RRT [standard means difference −0.08 (95% CI −0.26 to 0.09) and −0.11 (95% CI −0.37 to 0.16) day, respectively]. In subgroup analysis, earlier RRT was associated with a reduction in the in-hospital mortality among surgical patients (RR 0.78, 95% CI 0.64–0.96) and patients who underwent continuous renal replacement therapy (CRRT) (RR 0.80, 95% CI 0.67–0.96). Compared with later RRT, earlier initiation of RRT did not show beneficial impacts on patient outcomes. However, a lower rate of death was observed among surgical patients and in those who underwent CRRT. The included literature is highly heterogeneous and, therefore, potentially subject to bias. Further high-quality RCT studies are warranted.

22 August 2016 in Nephrology
Verified
Journal Article
Closed access
PDF file
Chih-Chung ShiaoChih-Chung Shiao
Chih-Chung Shiao
PWPei‐Chen Wu
Pei‐Chen Wu
VWVin-Cent Wu
Vin-Cent Wu
JLJui‐Hsiang Lin
Jui‐Hsiang Lin
HPHeng‐Chih Pan
Heng‐Chih Pan
O(on behalf of the Taiwan Consortium for Acute Kidney Injury Renal Diseases (CAKs)
on behalf of the Taiwan Consortium for Acute Kidney Injury Renal Diseases (CAKs)

4 December 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
WLWei-Ting Lin
Wei-Ting Lin
CLChih-Cheng Lai
Chih-Cheng Lai
SCShen-Peng Chang
Shen-Peng Chang
JWJian-Jhong Wang
Jian-Jhong Wang
The appropriate timing for initiating renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) remains unknown. This meta-analysis aims to assess the efficacy of early initiation of RRT in critically ill patients with AKI. The Pubmed, Embase and Cochrane databases were searched up to August 13, 2019. Only randomized controlled trials (RCTs) comparing the effects of early and late RRT on AKI patients were included. The primary outcome was 28-day mortality. Eleven RCTs including 1131 and 1111 AKI patients assigned to early and late RRT strategies, respectively, were enrolled in this meta-analysis. The pooled 28-day mortality was 38.1% (431/1131) and 40.7% (453/1111) in the patients assigned to early and late RRT, respectively, with no significant difference between groups (risk ratio (RR), 0.95; 95% CI, 0.78–1.15, I2 = 63%). No significant difference was found between groups in terms of RRT dependence in survivors on day 28 (RR, 0.90; 95% CI, 0.67–1.25, I2 = 0%), and recovery of renal function (RR, 1.03; 95% CI, 0.89–1.19, I2 = 56%). The early RRT group had higher risks of catheter-related infection (RR, 1.7, 95% CI, 1.01–2.97, I2 = 0%) and hypophosphatemia (RR, 2.5, 95% CI, 1.25–4.99, I2 = 77%) than the late RRT group. In conclusion, an early RRT strategy does not improve survival, RRT dependence, or renal function recovery in critically ill patients with AKI in comparison with a late RRT strategy. However, clinicians should be vigilant because early RRT can carry higher risks of catheter-related infection and hypophosphatemia during dialysis than late RRT.

16 October 2019 in Medicina
Verified
Journal Article
Open access
PDF file
LCLi-Chin Cheng
Li-Chin Cheng
SCShen peng Chang
Shen peng Chang
JWJian-Jhong Wang
Jian-Jhong Wang
SHSHENGYEN HSIAO
SHENGYEN HSIAO
CLChih-Cheng Lai
Chih-Cheng Lai
CCChien-Ming Chao
Chien-Ming Chao
Background and objectives: High-flow nasal cannula (HFNC) can be used as a respiratory support strategy for patients with acute respiratory failure (ARF). However, no clear evidence exists to support or oppose HFNC use in immunocompromised patients. Thus, this meta-analysis aims to assess the effects of HFNC, compared to conventional oxygen therapy (COT) and noninvasive ventilation (NIV), on the outcomes in immunocompromised patients with ARF. The Pubmed, Embase and Cochrane databases were searched up to November 2018. Materials and Methods: Only clinical studies comparing the effect of HFNC with COT or NIV for immunocompromised patients with ARF were included. The outcome included the rate of intubation, mortality and length of stay (LOS). Results: A total of eight studies involving 1433 immunocompromised patients with ARF were enrolled. The pooled analysis showed that HFNC was significantly associated with a reduced intubation rate (risk ratio (RR), 0.83; 95% confidence interval (CI), 0.74–0.94, I2 = 0%). Among subgroup analysis, HFNC was associated with a lower intubation rate than COT (RR, 0.86; 95% CI, 0.75–0.95, I2 = 0%) and NIV (RR, 0.59; 95% CI, 0.40–0.86, I2 = 0%), respectively. However, there was no significant difference between HFNC and control groups in terms of 28-day mortality (RR, 0.78; 95% CI, 0.58–1.04, I2 = 48%), and intensive care unit (ICU) mortality (RR, 0.87; 95% CI, 0.73–1.05, I2 = 57%). The ICU and hospital LOS were similar between HFNC and control groups (ICU LOS: mean difference, 0.49 days; 95% CI, −0.25–1.23, I2 = 69%; hospital LOS: mean difference, −0.12 days; 95% CI, −1.86–1.61, I2 = 64%). Conclusions: Use of HFNC may decrease the intubation rate in immunocompromised patients with ARF compared with the control group, including COT and NIV. However, HFNC could not provide additional survival benefit or shorten the LOS. Further large, randomized controlled trials are needed to confirm these findings.